Omnicell (OMCL)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$34.37-1.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · OMCL
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $34 OMCL trades at 16× p/e, below its 20× p/e peer median. Our $43 fair value sits well above the price. We hold it with medium confidence: quality doesn't explain valuation multiples in this sub-industry, so the peer comparison is a weak guide. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcff | 12M | $60.55 | — | — | Hist. CAGR | high |
| graham number | 12M | $36.82 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $33.50 | 10.1 | 3.07 | TTM | high |
| Peer P/FCF | 12M | $47.59 | 15.6 | 3.05 | TTM | high |
| Peer P/E | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $1.49/sh owner earnings.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $44.00 |
| 20.4 |
| 2.16 |
| TTM |
| high |
| Peer P/S | 12M | $51.49 | 1.9 | 26.93 | TTM | high |
| residual income | 12M | $27.66 | — | — | TTM | high |
| Own P/E history | 12M | $45.38 | 21.0 | 2.16 | TTM | high |
| triangulated | 12M | $47.85 | 20.4 | 2.35 | Triangulated | high |
| Peer P/FCF | 3Y | $47.80 | 15.6 | 3.07 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $45.76 | 20.4 | 2.25 | Analyst | medium |
| Peer P/S | 3Y | $52.33 | 1.9 | 27.37 | guidance | medium |
| Own P/E history | 3Y | $47.20 | 21.0 | 2.25 | Analyst | medium |
| Peer P/FCF | 5Y | $47.93 | 15.6 | 3.08 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $44.90 | 20.4 | 2.20 | Analyst | high |
| Peer P/S | 5Y | $51.35 | 1.9 | 26.86 | guidance | high |
| Own P/E history | 5Y | $46.32 | 21.0 | 2.20 | Analyst | high |